

Aetna Better Health® of Kentucky

Provider Notification: Policy Updates

CLINICAL PAYMENT, CODING AND POLICY CHANGES

Dear Provider:

We regularly augment our clinical, payment and coding policy positions as part of our ongoing policy review processes. In an effort to keep our providers informed, please see the below policy updates related to genetic testing. Tables 1 & 2 list the applicable codes. The policy updates will be effective for dates of service beginning **June 1, 2025.** Other exclusions/criteria may be applied based on correct coding/MUE.

Genetic Testing:

Based on professional society guidelines and federal agencies we will not cover genetic tests that are experimental, investigational, or unproven (EIU). For example, there is insufficient evidence that pharmacogenetic testing panels improve health outcomes. In addition, we require that the diagnosis is appropriate for the genetic test. For example, a personal and/or family history of BRCA-related cancers could be expected when breast cancer (BRCA) gene variant combinations are billed.

Codes listed in table 1 currently do not require a prior authorization.

Table 1		
CPT Code	CPT Description	
81283	IFNL3 GENE ANALYSIS RS12979860 VARIANT	
81540	ONCOLOGY TUM UNKNOWN ORIGIN MRNA 92 GENES	
81445	SO NEO GSAP 5-50DNA/DNA&RNA	
81450	HL NEO GSAP 5-50DNA/DNA&RNA	
81455	SO/HL 51/GT GSAP DNA/DNA&RNA	
0037U	TRGT GEN SEQ DNA 324 GENES	
81200	ASPA GENE ANALYSIS COMMON VARIANTS	
81205	BCKDHB GENE ANALYSIS COMMON VARIANTS	
81209	BLM GENE ANALYSIS 2281DEL6INS7 VARIANT	
81225	CYP2C19 GENE ANALYSIS COMMON VARIANTS	



81226	CYP2D6 GENE ANALYSIS COMMON VARIANTS
81227	CYP2C9 GENE ANALYSIS COMMON VARIANTS
81291	MTHFR GENE ANALYSIS COMMON VARIANTS
81381	HLA I TYPING HIGH RESOLUTION 1 ALLELE/ALLELE GRP
81225	CYP2C19 GENE ANALYSIS COMMON VARIANTS
81226	CYP2D6 GENE ANALYSIS COMMON VARIANTS
81381	HLA I TYPING HIGH RESOLUTION 1 ALLELE/ALLELE GRP
81243	FMR1 ANALYSIS EVAL TO DETECT ABNORMAL ALLELES
81244	FMR1 GENE ANALYSIS CHARACTERIZATION OF ALLELES
81201	APC GENE FULL SEQUENCE
81202	APC GENE KNOWN FAM VARIANTS
81203	APC GENE DUP/DELET VARIANTS
81435	HEREDITARY COLON CA DSORDRS
81241	F5 COAGULATION FACTOR V ANAL LEIDEN VARIANT
81291	MTHFR GENE ANALYSIS COMMON VARIANTS
81400	MOLECULAR PATHOLOGY PROCEDURE LEVEL 1
81220	CFTR GENE ANALYSIS COMMON VARIANTS
81223	CFTR GENE ANALYSIS FULL GENE SEQUENCE
81361	HBB COMMON VARIANTS
81400	MOLECULAR PATHOLOGY PROCEDURE LEVEL 1
81401	MOLECULAR PATHOLOGY PROCEDURE LEVEL 2
81381	HLA I TYPING HIGH RESOLUTION 1 ALLELE/ALLELE GRP
81420	FETAL CHROMOSOMAL ANEUPLOIDY GENOMIC SEQ ANALYS
81507	FETAL ANEUPLOIDY 21 18 13 SEQ ANALY TRISOM RISK
81291	MTHFR GENE ANALYSIS COMMON VARIANTS
81401	MOLECULAR PATHOLOGY PROCEDURE LEVEL 2
81405	MOLECULAR PATHOLOGY PROCEDURE LEVEL 6
81406	MOLECULAR PATHOLOGY PROCEDURE LEVEL 7
81243	FMR1 ANALYSIS EVAL TO DETECT ABNORMAL ALLELES
81329	SMN1 GENE ANALYSIS DOSAGE/DELET ALYS W/SMN2 ALYS
81408	MOLECULAR PATHOLOGY PROCEDURE LEVEL 9
81243	FMR1 ANALYSIS EVAL TO DETECT ABNORMAL ALLELES



In addition to the policy updates noted above - Effective for dates of service beginning **June 1, 2025**, Aetna Better Health of Kentucky will no longer require prior authorization for the set of codes listed in table 2. This is part of a larger optimization initiative intended to improve operational efficiency and reduce unnecessary provider administration activity. The same genetic testing policy updates will apply. Other exclusions/criteria may be applied based on correct coding/MUE.

Table 2		
CPT Code	CPT Description	
0048u	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)	
0134u	Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure)	
0101u	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with MRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])	
0130u	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure)	
81162	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) gene analysis; full sequence analysis and full duplication/deletion analysis (ie, detection of large gene rearrangements)	
81222	CFTR (cystic fibrosis transmembrane conductance regulator) (eg, cystic fibrosis) gene analysis; duplication/deletion variants	



81306	NUDT15 (nudix hydrolase 15) (eg, drug metabolism) gene analysis, common variant(s) (eg, *2, *3, *4, *5, *6)
81436	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis); duplication/deletion analysis panel, must include analysis of at least 5 genes, including MLH1, MSH2, EPCAM, SMAD4, and STK11

As always, do not hesitate to contact your Aetna Better Health Provider Relations Representative with any questions or comments.

Thank you for your valued partnership in caring for our members.

Questions?

If you have general questions about this communication, contact Provider Relations. You can call Provider Relations at **1-855-300-5528 (TTY: 711)**. We're here for you Monday through Friday, 7 AM to 7 PM ET.

Provider Services

Aetna Better Health of Kentucky

AetnaBetterHealth.com/Kentucky